– Exclusive access granted to Moderna for up to four immuno-oncology targets –
LONDON, UK I August 02, 2021 I Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.
Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and development and commercial milestone payments for each product successfully commercialized. In addition, Autolus would be entitled to receive royalties on net sales of all products commercialized under the agreement.
“We are pleased that Moderna has selected Autolus as a partner for certain mRNA-based therapeutics in oncology indications,” said Dr. Martin Pulé, founder and chief scientific officer of Autolus. “The use of our technology in Moderna’s mRNA platform underscores Autolus’ leadership in the development of innovative differentiated binder and cell programming technologies.”
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
SOURCE: Autolus Therapeutics
Post Views: 317
– Exclusive access granted to Moderna for up to four immuno-oncology targets –
LONDON, UK I August 02, 2021 I Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an agreement with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, granting Moderna an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus’ proprietary binders for up to four immuno-oncology targets.
Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and development and commercial milestone payments for each product successfully commercialized. In addition, Autolus would be entitled to receive royalties on net sales of all products commercialized under the agreement.
“We are pleased that Moderna has selected Autolus as a partner for certain mRNA-based therapeutics in oncology indications,” said Dr. Martin Pulé, founder and chief scientific officer of Autolus. “The use of our technology in Moderna’s mRNA platform underscores Autolus’ leadership in the development of innovative differentiated binder and cell programming technologies.”
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
SOURCE: Autolus Therapeutics
Post Views: 317
